AI Summary
STAAR reported preliminary Q2 2026 net sales above $90 million, more than doubling from $44.3 million a year earlier, fueled by China, APAC and Americas growth. While Middle East headwinds and ERP-related execution challenges weighed on some markets, distributor inventory is back within the targeted range, positioning the company for continued momentum ahead of the August 12 earnings release.
Sentiment Rationale
The >$90M Q2 preliminary sales mark represents a substantial YoY improvement and validates multi-regional demand, which could lift sentiment and valuation into the August 12 results. While unaudited and subject to revision, the magnitude and regional breadth support near-term upside despite ongoing ERP challenges and geopolitical headwinds.
Trading Thesis
Near-term bullish; consider positions ahead of August 12 earnings on strong regional demand.
Market-Moving
- Preliminary Q2 >$90M signals strong demand in key regions.
- ERP challenges caused near-term operational issues; fixes in Q3.
- Geopolitical/macroeconomic headwinds in Middle East/EMEA/APAC remain risk.
- End-Q2 distributor inventory within targeted range supports revenue ramp.
Key Facts
- Q2 2026 net sales exceed $90M, vs $44.3M in 2025.
- Growth driven by China, APAC, and Americas; EMEA ex-Middle East strong.
- Middle East headwinds and ERP-implementation challenges noted.
- Distributor inventory end-Q2 2026 within targeted range.
Companies Mentioned
- STAAR Surgical Company (STAA): Preliminary Q2 sales above $90M; near-term earnings catalyst; regional momentum.
Earnings
Category: Earnings. This is a quarterly results update with preliminary sales metrics signaling momentum, guiding near-term valuation; however, headwinds and ERP issues introduce some execution risk.